Drug company Merck to cut 1 jobs in 10 in Germany

by The Associated Press

(AP)—German drug maker Merck KGaA is to eliminate one out of every 10 jobs in its home country.

said Tuesday it would cut 1,100 of the 10,900 positions in its home country. It signed an agreement with employee representatives about the cost cuts. The company will try to find the cuts through either not filling the posts of people who leave or workers opting to take .

Merck has suffered development and marketing setbacks including the abandonment of its multiple sclerosis drug Cladibrine after it was rejected by EU regulators and questioned by the U.S. .

Merck KgaA has 40,000 workers in 67 countries. It's a different company from U.S.-based Merck & Co., Inc.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Merck KGaA suffers setback on cancer drug

Jul 05, 2012

German pharmaceuticals maker Merck KGaA said Thursday that phase III clinical trials of its gastric cancer drug Erbitux had shown no benefits for patients.

Merck says US rejects its MS drug

Mar 02, 2011

German pharmaceutical group Merck KgaA said Wednesday that the US Food and Drug Administration (FDA) has refused to approve use of its multiple sclerosis treatment Cladribine.

Facebook sidelines contested Merck profile page

Nov 29, 2011

Facebook will sideline a Merck page at the social network until a pair of US and German companies work out which one gets the online address, a source familiar with the matter told AFP.

Merck's Vioxx cases drag on

Aug 21, 2007

Lawsuits related to the painkiller Vioxx have little prospect of resolution for the thousands who have sued the drug company Merck, it was reported.

Recommended for you

Have a cold? Don't ask your doctor for antibiotics

6 hours ago

Antibiotic resistance is a major threat to public health. Resistance makes it harder for physicians to treat infections and can increase the chance patients will die from an infection. What is more, the treatment ...

Powdered measles vaccine found safe in early clinical trials

Nov 25, 2014

A measles vaccine made of fine dry powder and delivered with a puff of air triggered no adverse side effects in early human testing and it is likely effective, according to a paper to be published November 28 in the journal ...

Health care M&A leads global deal surge

Nov 23, 2014

In a big year for deal making, the health care industry is a standout. Large drugmakers are buying and selling businesses to control costs and deploy surplus cash. A rising stock market, tax strategies and ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.